Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line
Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic--glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested . We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy .
Publication Source (Journal or Book title)
Nanomedicine (London, England)
Byrne, C. E., Astete, C. E., Vaithiyanathan, M., Melvin, A. T., Moradipour, M., Rankin, S. E., & Knutson, B. L. (2020). Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line. Nanomedicine (London, England), 15 (10), 981-1000. https://doi.org/10.2217/nnm-2020-0010